374930-88-8

Basic information

• Product Name: 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE
• Synonyms: 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE;4-(5-BROMOPYRIMIDIN-2-YL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;4-(5-BROMOPYRIMIDIN-2-YL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER, 95+%;5-Bromo-2-[(N-Boc)piperazin-1-yl]pyrimidine;1-Boc-4-(5-bromopyrimidin-2-yl)piperazine;1-Piperazinecarboxylic acid, 4-(5-bromo-2-pyrimidinyl)-, 1,1-dimethylethyl ester;1-N-Boc-4-(5-broMopyriMidin-2-yl)piperazine;4-(5-bromo-2-pyrimidinyl)-1-piperazinecarboxylic acid tert-butyl ester
• CAS NO: 374930-88-8
• Molecular Formula: C₁₃H₁₉BrN₄O₂
• Molecular Weight: 343.22
• Product Categories: pharmacetical;Organohalides;Pyrimidine
• Mol File: 374930-88-8.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 451°Cat760mmHg
• Flash Point: 226.5°C
• Appearance: /
• Density: 1.414g/cm³
• Vapor Pressure: 2.53E-08mmHg at 25°C
• Refractive Index: 1.562
• Storage Temp.: 2-8°C(protect from light)
• PKA: 3.46±0.42(Predicted)
• CAS DataBase Reference: 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE(374930-88-8)
• EPA Substance Registry System: 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE(374930-88-8)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• Hazardous Substances Data: 374930-88-8(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-(4-BOC-piperazin-1-yl)pyrimidine is a chemical compound with the molecular formula C11H16BrN5O2. It is a pyrimidine derivative and contains a bromine atom as well as a piperazine moiety with a BOC (tert-butoxycarbonyl) protecting group. 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE has potential applications in medicinal chemistry and drug development, as it can be used as a building block in the synthesis of various pharmaceutical compounds. It is a valuable intermediate in the synthesis of novel heterocyclic compounds and may have therapeutic potential in the treatment of certain diseases. Overall, 5-Bromo-2-(4-BOC-piperazin-1-yl)pyrimidine is a versatile chemical building block with potential applications in the pharmaceutical industry.

InChI:InChI=1/C13H19BrN4O2/c1-13(2,3)20-12(19)18-6-4-17(5-7-18)11-15-8-10(14)9-16-11/h8-9H,4-7H2,1-3H3

Upstream product

• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 32779-37-6 2,5-dibromopyrimidine 

Downstream Products

• 470478-90-1 tert-butyl 4-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate 
• 1310685-40-5 D-750901 
• 1310685-42-7 4-(4-(5-benzylpyrimidin-2-yl)piperazin-1-yl)-2-phenylquinazoline 
• 1310685-49-4 (4-(5-benzylpyrimidin-2-yl)piperazin-1-yl)(4-(quinazolin-4-ylamino)phenyl)methanone 
• 1310685-50-7 (4-(5-benzylpyrimidin-2-yl)piperazin-1-yl)(4-((quinazolin-4-ylamino)methyl)phenyl)methanone 
• 1310685-54-1 (4-(5-benzylpyrimidin-2-yl)piperazin-1-yl)(3-(2-phenylquinazolin-4-ylamino)phenyl)methanone 
• 1310685-55-2 (4-(5-benzylpyrimidin-2-yl)piperazin-1-yl)(4-(2-phenylquinazolin-4-ylamino)phenyl)methanone 
• 1310685-56-3 (4-(5-benzylpyrimidin-2-yl)piperazin-1-yl)(4-((2-phenylquinazolin-4-ylamino)methyl)phenyl)methanone 
• 1310685-48-3 D-750776 

Relevant articles and documents

Synthesis and biological evaluation of disubstituted pyrimidines as selective 5-HT2C agonists

Here, we describe the synthesis of disubstituted pyrimidine derivatives and their biological evaluation as selective 5-HT2C agonists. To improve selectivity for 5-HT2C over other subtypes, we synthesized two series of disubstituted pyrimidines with fluorophenylalkoxy groups at either the 5-position or 4-position and varying cyclic amines at the 2-position. The in vitro cell-based assay and binding assay identified compounds 10a and 10f as potent 5-HT2C agonists. Further studies on selectivity to 5-HT subtypes and drug-like properties indicated that 2,4-disubstituted pyrimidine 10a showed a highly agonistic effect on the 5-HT2C receptor, with excellent selectivity, as well as exceptional drug-like properties, including high plasma and microsomal stability, along with low CYP inhibition. Thus, pyrimidine 10a could be considered a viable lead compound as a 5-HT2C selective agonist.

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.